Canon & iPF are either registered trademarks or trademarks of Canon Inc., Japan. Epson & Epson Stylus are either registered trademarks or trademarks of Seiko Epson Corporation, Japan. Apple & Mac OSX are trademarks of Apple Inc., registered in the U.S. The images used for the Mirage screenshots are copyright protected and are sourced from Douglas Dubler, Vincent Versace, Hans van Ommeren and the liveprint collection, the images are taken out of the collections from OKAPIA KG Michael Grzimek & Co, Renate Scherra and Lutz Fohrer.Īdobe™, Adobe™ InDesign™, Adobe™ Photoshop™, Adobe™ Illustrator™, Adobe™ Acrobat™ & Adobe™ Photoshop™ Elements are either registered trademarks or trademarks of Adobe™ Systems Incorporated in the United States and/or other countries. None of the text and screenshots on this website may be copied, published or used in any other way without prior written permission by DINAX GmbH. Download 22.8 MB Edit program info Info updated on: Software Informer Download popular programs, drivers and latest updates easily X-Mirage is a professional AirPlay server that allows you to wirelessly stream contents or mirror iPhone, iPad, and iPod screen to any PC. The software Mirage is copyright protected and property of DINAX GmbH, Neuss - Germany. Mirage™ and DINAX™ are registered trademarks of DINAX GmbH, Neuss - Germany. Patients with any evidence of distant metastases.Copyright notes: The software Mirage is the property of: DINAX GmbH. Patients with neuroendocrine or small cell carcinoma of the prostate I had huge problems with airserver (my entire network crashed every time I connected to it) and x-mirage works flawlessly for me.Ability to understand, and willingness to sign, the written informed consent.prostate-specific membrane antigen positron emission tomography and axumin scan) can supplant a bone scan if performed first High-risk: technetium bone scan, CT abdomen/pelvis if MSKCC nomogram predicts >10% probability of lymph node involvement.Please download the latest version from: /download. Unfavorable intermediate-risk: technetium bone scan, CT abdomen/pelvis if MSKCC nomogram predicts >10% probability of lymph node involvement X-Mirage for Mac 2.10.4 released It is a 64-bit version and fully compatible with macOS High Sierra 10.13.4.Favorable intermediate-risk: CT abdomen/pelvis if Memorial Sloan Kettering Cancer Center (MSKCC) nomogram predicts >10% probability of lymph node involvement.The trial is pragmatically designed to detect an improvement in acute GU toxicity. Staging workup as recommended by the National Comprehensive Cancer Network (NCCN) on the basis of risk grouping: The MIRAGE trial is the first and only randomized trial to rigorously evaluate whether the theoretical advantages of MRI-guided radiotherapy for PCa translate into a meaningful clinical improvement. No evidence of disease beyond the prostate and/or seminal vesicles (i.e., no suspicious pelvic lymph nodes or presence of metastatic disease outside the pelvis).Histologically confirmed, clinical localized adenocarcinoma of the prostate.GROUP II: Patients undergo 5 fractions of MRI-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.Īfter completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 4 years, and then yearly thereafter. GROUP I: Patients undergo 5 fractions of CT-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity. OUTLINE: Patients are randomized to 1 of 2 groups. To observe the proportion of SBRT fractions for which on-line adaptive radiotherapy is required due to changes in organ-at-risk anatomy. To determine whether there are differences in 5-year biochemical recurrence-free survival (BCRFS) following MRI-guided SBRT. To quantify the temporal changes in patient-reported quality of life (QOL) outcomes, as assessed by the Expanded Prostate Cancer Index-26 (EPIC-26), International Prostate Symptom Scores (IPSS), and Sexual Health Inventory for Men (SHIM) QOL indices, following MRI-guided SBRT. To determine whether there are differences in 5-year cumulative incidences of late grade >= 2 GU and GI physician-reported toxicity, following MRI-guided SBRT versus CT-guided SBRT. To determine whether there are differences in acute grade >= 2 gastrointestinal (GI) toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 scale, following MRI-guided SBRT versus CT-guided SBRT. To determine whether (MRI)-guided stereotactic body radiotherapy (SBRT) improves acute physician-scored genitourinary (GU) toxicity when compared with standard computed tomography (CT)-guided SBRT for prostate cancer (PCa). Why Should I Register and Submit Results? Download X-Mirage from our website and install it on your Mac, you can use it for 7 days without buying it.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |